Skip to main content
. 2021 May 4;134(11):1324–1328. doi: 10.1097/CM9.0000000000001510

Figure 1.

Figure 1

Efficacy of secukinumab 150 mg (A) and secukinumab 300 mg (B) in patients with moderate-to-severe plaque psoriasis over 24 weeks of treatment. The PASI 75, PASI 90, and PASI 100 response rates were evaluated at weeks 5, 12, 16, and 24. PASI: Psoriasis area and severity index.